Home / Transcripts / Spectral AI, Inc. (MDAI) · November 11, 2025

Spectral AI, Inc. (MDAI) Earnings Call Transcript

November 11, 2025

NASDAQ US Health Care Health Care Equipment and Supplies earnings 26 min

Earnings Call Speaker Segments

Sara Prendergast executive
#1

Thanks, Nick. Hello, everyone, and good afternoon. We appreciate you being here for Spectral AI's conference call covering financial results for the third quarter of 2025. Dr. DiMaio, who serves as Chairman of the Board for the company, and Vincent Capone, the company's Chief Financial Officer, are our speakers today. Prior to starting, I want to remind all of you that some statements delivered on this call are forward-looking statements as defined under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, which includes statements about the company's strategy, plans, objectives, initiatives, and financial outlook. On this call, terms such as estimates, projected, expects, anticipates, forecasts, plans, intends, believes, seeks, may, will, should, future, propose, along with variations of these terms or similar expressions, or the negative forms of such terms or expressions, are meant to identify forward-looking statements; such forward-looking statements do not guarantee future performance, conditions, or results, and they involve a number of known and unknown risks, uncertainties, assumptions, and other important factors, many of which lie outside the company's control, that might cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Therefore, listeners are warned against placing undue reliance on any forward-looking statements. Investors ought to carefully consider the above factors and the other risks and uncertainties described in the risk factors sections of the company's filings with the SEC, including the registration statement and the other documents filed by the company; these filings identify and address additional important risks and uncertainties that might cause actual events and results to differ materially from those contained in the forward-looking statements. Having said that, I'd like to hand the call over to Dr. DiMaio, Spectral AI's Chairman of the Board.

Michael DiMaio executive
#2

Sarah, thanks so much, and good afternoon, everybody. We're glad you could be with us today for the conference call on our financial results for the third quarter. It's a real pleasure to walk you through how our operations performed through the third quarter of 2025. As I've said on earlier earnings calls, at Spectral AI I stick to a mantra of finance, focus, and finish. I think we're advancing across each of those three phases as we wrap up our 2025 calendar year. After our submission to the FDA during the second quarter of 2025, we've kept working on developments related to our DeepView System. I want to talk about further developments from the third quarter of 2025 as follows. First, finance. Our cash balance remained unchanged at $10.5 million compared with the second quarter of 2025. We keep watching our operating efficiencies, and there were quite a few stock option and warrant exercises that helped drive the persistently high level of cash reserves our company holds. Beyond that, as we announced in October, we closed one more registered direct offering of our common stock, which brought an extra $7.6 million in cash reserves onto the company's balance sheet. With total cash on hand exceeding $10 million at the close of September 2025, a tightly controlled spending pace, and the extra funding from that registered direct offering, Spectral AI holds substantial financing for the foreseeable future, which lets us keep pursuing our product commercialization efforts, among them the planned U.S. launch of our DeepView System next year. Second, focus, which is the FDA submission. Our submission to the FDA, filed in June of this year, represented a huge milestone in the development of our company. I take pride in our team for the hard work and commitment they showed in hitting that highly important timeline. That submission is clearly a central driver behind our business's evolution. We keep having additional interactions with the FDA regarding our de novo application, though things have slowed somewhat given the current U.S. government shutdown that all of us are dealing with. We keep pressing ahead with the de novo application at full speed, just as we've said. Third, finish. Finally, finish is the thing we keep concentrating on as we collaborate with our BARDA partners to bring the DeepView System and the device into the commercial marketplace. We remain focused on releasing next year and getting ready to roll out a commercialization strategy that we've talked about and will keep honing as we approach that milestone. We continue to pursue a very broad set of applications and indications, in addition to burns, for which we hold a CPT III code, along with further indications that will expand the marketplace. The support we've received from the burn community and at burn conferences has been outstanding, with our abstracts presented at national forums as well as in publications and international publications. That reinforces even more what's taking place with our system, along with the backing it's getting from the burn and wound community as a whole. Once more, I appreciate your focus on our company, and having said that, I'll hand things off to our Chief Financial Officer, Vince Capone. Vince.

Vincent Capone executive
#3

Thanks, Dr. DiMaio. I appreciate everyone being here this afternoon. Our earnings release came out today, and it includes more specifics about our operating results; we'll also be submitting our Form 10-Q to the SEC later on this week. So with that said, my comments will center on a few chosen highlights and important items. Research and development revenue for the third quarter of 2025 dropped to $3.8 million, down from $8.2 million during the same quarter a year ago. That decline stems from the lower reimbursements we expected under the BARDA Project Bioshield contract, which the company was awarded in September of 2023; during the third quarter of 2025, after our FDA de novo submission, we've had fewer direct labor, clinical trial, and other reimbursed costs than we did in the prior year's quarter. Gross margin fell to 42.7% from 44.8% in last year's third quarter, driven by a smaller proportion of direct labor relative to our total reimbursed costs under the BARDA Project Bioshield contract compared with the prior year's quarter. General and administrative expenses came in at $5 million for the third quarter of 2025, versus $4.6 million for the third quarter of 2024; that rise is due to higher third-party advisor and consulting costs along with more non-billable work unconnected to the BARDA Project Bioshield contract. The company posted a net loss of $3.6 million for the third quarter of 2025, compared with a net loss of $1.5 million in the third quarter of the prior year, once again reflecting the lower research and development revenue and the greater general and administrative expenses versus the prior year's third quarter. Despite a $2.1 million larger net loss in the third quarter of 2025 than in the third quarter of 2024, the company is reporting a net loss of $8.6 million for the first nine months of 2025, compared with a net loss of $7.4 million for the first nine months of 2024, which shows our attention to managing the overall cost structure. As of September 2025, shares outstanding stood at 27,251,034. Turning to the balance sheet, as Dr. DiMaio mentioned earlier, cash and cash equivalents as of September 30, 2025 came to $10.5 million, higher than the $5.2 million recorded on December 31st, 2024. Our cash balance has stayed steady since June 30, 2025. That mainly results from stock options and warrants being exercised during the third quarter of 2025 and our ongoing management of operating expenses throughout the third quarter of 2025. Keep in mind that this cash balance excludes the gross proceeds of $7.6 million in additional funding the company received related to our registered direct offering in October 2025; given our substantial cash reserves, our disciplined approach to managing operational costs and expenses, we believe this funding level gives the company enough capital for the foreseeable future. When it comes to 2025, our revenue guidance is being cut, moving from $21.5 million down to $18.5 million. This lower outlook accounts for the work we expect to lose on the BARDA Project Bioshield contract now that the FDA submission has gone in, plus certain scheduling impacts tied to the U.S. government shutdown, which in our view will mostly be recovered during the first half of 2026. I'd also point out that no sales of the DeepView System for the burn indication in the U.K. or Australia are factored into this guidance. We appreciate everyone's time and attention today. With that, operator, please open the line so our analysts can ask questions. Sure. Izzy, thank you for joining the call. Yes, Izzy, our FDA submission continues to move forward as we see it; we don't anticipate any delays pushing our FDA submission into 2026. In fact, we're excited this week about the possibility of the government ending the shutdown. Certain discussions with BARDA — some of the talks we've had with their teams, and the group working on continued development of our DeepView System — have slipped. In the end, we mostly view this as a matter of timing, since nothing has shifted regarding when we hope and expect to receive FDA clearance for our device in the first half of 2026. That also goes for the ongoing work under the BARDA contract, which as you surely know extends through the close of the first quarter of 2026, at least for the base phase. Beyond that, it's simply a broad deceleration in work with our BARDA partners. I hope that addresses your question. Yeah, it does. Thank you; that's helpful. I realize it's early to be considering 2026 guidance, but you mentioned expecting part of this revenue to be recovered next year. I was wondering whether you could offer at least some qualitative color on how that will be paced or cadenced across next year. Sure. Izzy, we've consistently projected that 2026 will generally be a down year for revenue compared with where we stood in 2024 and in 2025. What we forecast right now is roughly flat from 2025 to 2026. There could be a slight dip in total revenue. We're still working through it. Clearly, quite a few assumptions go into that, but my expectation is that 2026 will look, on the revenue side, probably a bit lower than 2025, though I'm not sure it will differ all that materially; it's a transition year for us as we aim to commercialize the device. We view 2027 and, of course, 2028 as important years for the company's growth; that's helpful. And then one last thing from me. I know multiple units have been placed in international markets. I was curious what kind of feedback has come back from those sites and how you're applying it to shape your preparations for the U.S. launch. Thanks for taking the question.

Michael DiMaio executive
#4

Yes. If you don't mind, I'll handle that one. I appreciate the question — for someone like me who practices clinically, this matters a great deal. What I can tell you is that responses from sites beyond the U.S. have been extremely favorable. Among the things people have said: it's simple to operate, quite beneficial, and beyond the spoken feedback we've received, a variety of papers and abstracts have either come out or are in the process of being published to document this. We've also taken some of that input and applied it toward particular modifications or small tweaks to the device that we intend to build into the upcoming version of our Phoenix Device. To wrap up, the device has been received very well; it's been straightforward to use for both physicians and non-physician healthcare providers, and it has genuinely made caring for burn patients outside the United States easier.

Vincent Capone executive
#5

Thank you for the question.

Carl Byrnes analyst
#6

Congrats, and I appreciate you taking the question. What I'd like to know is where things stand with the FDA — how have those conversations been going? Have they come back with anything else they want, or are there still open items tied to the filing? Or has the back-and-forth been fairly smooth and straightforward? I've got one short follow-up as well. Thanks.

Michael DiMaio executive
#7

Yes, thank you. Dr. DiMaio here. I appreciate that question, since, as you put it, this is the second piece I brought up — the FDA focus. What I can tell you is that our interactions with the FDA have been extremely frequent and positive. Naturally, there are specific tweaks and inquiries they've raised for us, along with other items. I likely couldn't — or shouldn't — get into those in a public setting. Doing so would probably run afoul of certain FDA rules. It's enough to say that our communications have been very good. A key element here is the statistical analysis plan, or SAP, which is essentially the core of the artificial intelligence algorithm, and the reception to it has been quite favorable. That was the piece I personally worried about most, and it appears to have gone extremely well. Our data science teams have performed exceptionally. There's further testing on the horizon that we'll be examining — be it extra human factors studies or added reliability testing — which we're currently talking over with the FDA, and we're obtaining clearance and clarity on those points. After we wrap that up, we expect to keep moving forward. To sum up, the interaction has been solid. We've supplied extra information, and we actually have calls lined up with the FDA over the coming couple of weeks to get more clarification. Thank you.

Carl Byrnes analyst
#8

Great. Perfect. Excellent. I have one brief question to add. Regarding SnapShot, do you have any news about how the handheld module is coming along? Thanks.

Michael DiMaio executive
#9

That's a good question. I appreciate you asking it too, about the handheld. The response is an emphatic yes. Further work on it is underway. This is mainly a military initiative, with the military providing the funding, as you're aware. The feedback we've received has been positive—they're pleased with the initial design of the handheld unit—and right now it's undergoing the testing the military mandates, which covers both hot and cold temperature conditions. We've already secured some additional backing, and we're pursuing more, with expectations that further support will come through from the U.S. military so we can keep advancing that device for military applications. At the same time, we're in talks about using that same or a comparable form factor for civilian purposes, and those discussions are ongoing as well. What it comes down to is this: we're using the military as our foundation, our jumping-off point, to build a civilian version of a device that works much the same way. Let me make this clear to you and to everyone else — over the near and medium term, we fully expect the cart-based device to remain part of the picture, since that's the product BARDA contracted us to deliver. Burn units can put it to use with great ease. It's bigger, and you'll find it in the OR, the ER, and similar settings. As we see it, the handheld unit adds to the cart-based device and works alongside it — it isn't meant to take its place. Also, I want to mention that our intention is for the cart-based unit to serve as the foundation for a 510(k) submission covering the handheld version. The two share comparable technology, a comparable camera, and so on. This should make it easier for us to move our technology forward from the cart-based format to the hand-based one. Thanks.

Carl Byrnes analyst
#10

Excellent, thank you. That is quite useful. And once more, the handheld is financed via MTEC and DHA, right?

Michael DiMaio executive
#11

Yes, that is right. Correct, sir.

Carl Byrnes analyst
#12

Great.

Michael DiMaio executive
#13

Indeed. I have been placing less emphasis on that — not because I want to downplay it on account of the military as such, but also because I want to stress that the civilian market is something we are examining too. That's right, the diversion happening right now is paid for by Department of Defense units known as MTEC and DHA. You've got that right.

Carl Byrnes analyst
#14

Great, thank you very much.

John Vandermosten analyst
#15

Thanks, and good evening to everyone. To kick things off, I'm hoping to get a picture of where things stand with your commercialization prep work, and I wanted to ask whether adding a Chief Commercial Officer or a Chief Operations Officer is something you're considering. Beyond that, on the same topic, could you speak to what's underway regarding market access, distribution, marketing, and long-stay distribution as we head through the coming months toward the target action date?

Michael DiMaio executive
#16

John, I appreciate that question — it's a good one. Naturally, that falls under the third F, which stands for finish. Let me just go through these without any set order. There's already someone with us whose role is commercialization, and that individual is also handling the processing side of things. Within the 2026 budget, we've allocated for an additional four headcount—four FTEs—that we intend to bring in soon, so we can support Salesforce along with other pieces of what we refer to as professional education. One more thing to keep in mind: a portion of those expenses sits inside the BARDA budget, and that lets us offset part of what we spend during the early commercialization phase. Then, naturally, there's more to it: we're discussing the burn care community. As your familiarity with our research studies tells you, America has 137 burn units, and a substantial portion of them have taken part in our research trials. My view—and I'd make this argument—is that we hold a strong advantage with the group we plan to sell to first. They know this technology quite well, and they're eager to have it once the FDA grants federal clearance. Finally — and this could matter just as much — once FDA clearance comes through, the BARDA agreement carries provisions designed to support getting these devices placed into burn centers first and then further out. On that front, my view is that we're starting from a solid base: the right team and the money are already there to kick off the commercial launch, and we'll be scaling things up too in order to make it happen.

John Vandermosten analyst
#17

All right, that sounds positive. You gave a number of talks at the European Burn Association, so I wanted to ask what kind of reception the audience gave them and just who made up that audience. I'm aware it took place in Europe. My understanding is that it was in Germany. Does this let you extend farther east, I suppose, moving out from the U.K. so that additional health groups become interested in adopting the device?

Michael DiMaio executive
#18

Yes, sir, John. Once more, that's a terrific question, and I appreciate it. What I can tell you is that burn meetings were held in the U.K; and in Germany, and attending them were people from the burn communities in those countries, along with people from the U.S. burn community. We presented at each of those meetings. It isn't that I'm biased, but the reception our presentations got was excellent, along with one very, very common request: when would the product become available in those places? Units are already in place for us in the U.K. In fact, today we held conversations regarding growth into the European market, in both Western and Eastern parts, and those conversations are coming up soon. Our intention is to move ahead with securing clearance from UKCA and CE mark too. The device currently in the U.K. is set to be upgraded, drawing on what we've gained from the U.S. market and from the FDA. To sum up, yes, our plan is to expand into the U.K. and portions of Europe and possibly even further out. At present, naturally, the U.S. is where our main attention goes. Yes, outside the U.S. is where the secondary and tertiary attention will go.

John Vandermosten analyst
#19

Understood. That wraps up my queries, with the final one concerning the Spectral IP deal. I recall it was made public, but I haven't come across any updates, so I wanted to check on where that stands or what its current situation is.

Michael DiMaio executive
#20

Vince.

Vincent Capone executive
#21

Appreciate that, Dr. DiMaio. All right, I'll handle this question. John, it's nice to hear from you. Thanks for joining us today. So, regarding the Spectral IP along with the SIM IP deal that is presently moving through the SEC — my expectation, based on what I know as of today, is that those filings are going to be reviewed, and I'd anticipate that this transaction likely wraps up in Q1 of 2026. I'd also expect that you will see something reflected in our financials, probably during the first quarter of 2026, related to that transaction.

John Vandermosten analyst
#22

Excellent. Very well. Thanks, Vince. Thanks, Dr. DiMaio.

Michael DiMaio executive
#23

John, many thanks to you.

Vincent Capone executive
#24

Thanks, John.

Michael DiMaio executive
#25

We appreciate you joining us once more and for the ongoing interest you've shown in Spectral AI. As I laid out, we're quite happy with how things are moving along those three Fs, and we stay hopeful about what lies ahead for our growth. Our efforts remain focused on the three principles I described earlier, and we expect to share more updates soon regarding how we're advancing toward those objectives. My thanks go out to all of you on this call, and I hope you have a wonderful evening.

Operator operator
#26

That brings us to the end of this call. We appreciate your joining us for today's presentation. You're free to disconnect at this point.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Spectral AI, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Spectral AI, Inc. earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.